Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.62 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.62 |
| ▸ | PSMB8 | P28062 | 7/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.60 |
| ▸ | STAT3 | P40763 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | PTGES | O14684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46216 | 0.89 | PTPN12 (0.77) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL6742617 | 0.89 | PTPN12 (0.77) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL29665060 | 0.88 | LCK (0.73) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL21760925 | 0.86 | MEN1 (0.63) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL14426544 | 0.86 | PSMB8 (0.77) | MEN1KMT2APOLBPTPN12PTPN22 | |
| SCHEMBL14426532 | 0.86 | PSMB8 (0.77) | MEN1KMT2APOLBPTPN12PTPN22 | |
| SCHEMBL6790545 | 0.85 | PTPN12 (0.77) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL30115002 | 0.84 | POLB (0.70) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL684272 | 0.82 | ENPP2 (0.83) | MEN1KMT2APOLBPSMB8ENPP2 | |
| SCHEMBL29415356 | 0.81 | LCK (0.71) | MEN1KMT2APOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180560-B2 | Compositions and methods to treat solid tumors | WAYNE STATE UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3682947-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | GB006, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3243821-B1 | PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18 | GB006 INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190309073-A1 | COMPOSITIONS AND METHODS TO TREAT SOLID TUMORS | WAYNE STATE UNIVERSITY (US) | 2019-10-10 | — | — | US | disclosed |
| EP-2838614-B1 | COMPOSITIONS FOR REGULATING INTEGRINS | GB006 INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-10336827-B2 | Compositions and methods to treat solid tumors | WAYNE STATE UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-10239871-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3243821-A1 | PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18 | Adhaere Pharamaceuticals, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2591092-B1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | ADHAERE PHARAMACEUTICALS INC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170121410-A1 | COMPOSITIONS AND METHODS TO TREAT SOLID TUMORS | WAYNE STATE UNIVERSITY (US) | 2017-05-04 | — | — | US | disclosed |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2012005800-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | ADHAERE PHARAMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239871-B2 | Compounds and methods for regulating integrins | ITGA2, ITGB2, ITGA2B | MEN1 2635/4885KMT2A 2195/4885POLB 3373/4885 |
| US-20170121410-A1 | COMPOSITIONS AND METHODS TO TREAT SOLID TUMORS | ITGB8, MMP8, FUT8 | MEN1 3438/4885KMT2A 2866/4885POLB 738/4885 |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ITGB8, ITGB3, ITGAM | MEN1 1586/4885KMT2A 2448/4885POLB 4329/4885 |
| US-20190309073-A1 | COMPOSITIONS AND METHODS TO TREAT SOLID TUMORS | ITGB8, MMP8, ITGA8 | MEN1 3142/4885KMT2A 2746/4885POLB 737/4885 |
| US-10336827-B2 | Compositions and methods to treat solid tumors | ITGB8, MMP8, ITGA8 | MEN1 3142/4885KMT2A 2746/4885POLB 737/4885 |
| US-11180560-B2 | Compositions and methods to treat solid tumors | ITGB8, MMP8, ITGA8 | MEN1 3142/4885KMT2A 2746/4885POLB 737/4885 |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | MEN1 2635/4885KMT2A 2195/4885POLB 3373/4885 |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | MEN1 2635/4885KMT2A 2195/4885POLB 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.